ASPH inhibition reveals differential gene expression patterns in HPV-positive and HPV-negative cell lines
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F24%3A10486123" target="_blank" >RIV/00216208:11310/24:10486123 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
ASPH inhibition reveals differential gene expression patterns in HPV-positive and HPV-negative cell lines
Popis výsledku v původním jazyce
Cancer is associated with alterations in key cellular pathways, including the aspartate ββ-hydroxylase (ASPH) pathway, an oncogene upregulated in various carcinomas that plays a crucial role in tumor progression and metastasis. To elucidate the mechanisms of ASPH oncogenicity, we examined the effects of ASPH inhibition in human papillomavirus (HPV) HPV)-positive (CRL CRL-3240, HeLa) and HPV HPV-negative (FaDu, MCF MCF-7) cell lines. Inhibition of ASPH's catalytic activity using the small molecule inhibitor MO MO-II-1151 resulted in a significant reduction in proliferation, migration, and invasiveness of these tumor cells.Transcriptome analysis via bulk RNA sequencing revealed 2387 and 2350 differentially expressed genes in hypoxic and normoxic conditions, respectively, compared to controls.Notably, 1460 genes in hypoxia and 1325 in normoxia were significantly downregulated, particularly those involved in cell cycle regulation, DNA replication, and epithelial epithelial-mesenchymal transition (EMT). RT RT-qPCR validated the downregulation of key genes (IL7R, LY6D, LY6E, LY6K, TRIP13, SUV39H1, ELAVL2, WNT10B) in at least three cell lines. The interleukin 7 (IL7) receptor gene (IL7R) was consistently downregulated across all cell lines. IL7R, shared by the IL7 and thymic stromal lymphopoietin (TSLP) receptors, interacts with JAK1/3 and JAK1/2 through their intracellular domains. Western blot analysis showed that MOMO-II-1151 or tofacitinib (a Janus kinase inhibitor) reduced key JAK/STAT pathway components, including JAK2/3, STAT5, BCL BCL-2, MCL1, and cyclin D1 in CRL CRL-3240 and HeLa cells, indicating that ASPH inhibition primarily targets the JAK/STAT pathway via IL7. These findings suggest the potential of targeting IL7/TSLP receptor signaling and ASPH activity as therapeutic strategies in cancer treatment.
Název v anglickém jazyce
ASPH inhibition reveals differential gene expression patterns in HPV-positive and HPV-negative cell lines
Popis výsledku anglicky
Cancer is associated with alterations in key cellular pathways, including the aspartate ββ-hydroxylase (ASPH) pathway, an oncogene upregulated in various carcinomas that plays a crucial role in tumor progression and metastasis. To elucidate the mechanisms of ASPH oncogenicity, we examined the effects of ASPH inhibition in human papillomavirus (HPV) HPV)-positive (CRL CRL-3240, HeLa) and HPV HPV-negative (FaDu, MCF MCF-7) cell lines. Inhibition of ASPH's catalytic activity using the small molecule inhibitor MO MO-II-1151 resulted in a significant reduction in proliferation, migration, and invasiveness of these tumor cells.Transcriptome analysis via bulk RNA sequencing revealed 2387 and 2350 differentially expressed genes in hypoxic and normoxic conditions, respectively, compared to controls.Notably, 1460 genes in hypoxia and 1325 in normoxia were significantly downregulated, particularly those involved in cell cycle regulation, DNA replication, and epithelial epithelial-mesenchymal transition (EMT). RT RT-qPCR validated the downregulation of key genes (IL7R, LY6D, LY6E, LY6K, TRIP13, SUV39H1, ELAVL2, WNT10B) in at least three cell lines. The interleukin 7 (IL7) receptor gene (IL7R) was consistently downregulated across all cell lines. IL7R, shared by the IL7 and thymic stromal lymphopoietin (TSLP) receptors, interacts with JAK1/3 and JAK1/2 through their intracellular domains. Western blot analysis showed that MOMO-II-1151 or tofacitinib (a Janus kinase inhibitor) reduced key JAK/STAT pathway components, including JAK2/3, STAT5, BCL BCL-2, MCL1, and cyclin D1 in CRL CRL-3240 and HeLa cells, indicating that ASPH inhibition primarily targets the JAK/STAT pathway via IL7. These findings suggest the potential of targeting IL7/TSLP receptor signaling and ASPH activity as therapeutic strategies in cancer treatment.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/LX22NPO5103" target="_blank" >LX22NPO5103: Národní institut virologie a bakteriologie</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů